

# Research Powered by Komodo Data at ISPOR 2026

## Poster Session 1: Monday, May 18, 10:30 am to 1:30 pm

CO11	<a href="#">Impact Of GLP-1 Receptor Agonist (GLP-1 RAS) Persistence Versus Discontinuation on Cardiometabolic Measures in Polycystic Ovary Syndrome (PCOS) Over a Two-Year Follow-Up</a>
CO24	<a href="#">Real-World Comparative Effectiveness of Lutetium-177-PSMA-617 Versus Cabazitaxel for Metastatic Castration-Resistant Prostate Cancer</a>
CO36	<a href="#">A Real-World Retrospective Cohort Study Characterizing Treatment Patterns Among Patients With Lupus Nephritis in the United States</a>
EE69	<a href="#">Healthcare Resource Utilization (HCRU) in Pediatric Patients With Hereditary Angioedema (HAE) in the United States: A Matched Study Using Large Insurance Claims</a>
EE87	<a href="#">Economic Impact of Delayed Access to Finerenone Due to Formulary Restrictions in Chronic Kidney Disease (CKD) and Type 2 Diabetes (T2D)</a>
EE46	<a href="#">Cost-Effectiveness of Abiraterone, Apalutamide, Enzalutamide, and Docetaxel Doublets for Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Evidence Analysis</a>
EPH30	<a href="#">Claims Data for Post-Market Safety Investigations: Lessons From a Real-World Oncology Cohort</a>
HSD7	<a href="#">Characterizing Facioscapulohumeral Muscular Dystrophy (FSHD) Longitudinal EHR Activity Using a Large US Electronic Health Records Database Linked to Claims, 2020-2025</a>
HSD17	<a href="#">Real-World Demographic and Treatment Characteristics of Patients With Congenital Myasthenic Syndrome in the United States</a>
MSR23	<a href="#">Clinical Validation of a Machine-Learning-Enriched Immune-Mediated Necrotizing Myopathy Cohort Using Linked Laboratory and Claims Data</a>
RWD15	<a href="#">First-Line CDK4/6 Inhibitor Use in Metastatic Breast Cancer: Real-World Data From a Retrospective US Cohort Study</a>
RWD22	<a href="#">Real-World Endpoint Mapping and Identification of Evolving Phenotypes of Pompe Disease Using Machine Learning</a>

## Poster Session 2: Monday, May 18, 4 to 7 pm

 CO47	<a href="#">Impact of Lipid-Lowering Therapies on Triglyceride Levels in US Patients With ASCVD in the Real-World</a>
 EE135	<a href="#">Characterizing Age-Related Patterns in Healthcare Costs and Utilization Among People Living With Angelman Syndrome in the United States</a>
 EPH49	<a href="#">Type 1 and Type 2 Diabetes Mellitus Identification Using ICD-10-CM Codes Among New Users of Antidiabetics: A Real-World Study From Komodo Research Dataset</a>
 HPR44	<a href="#">Racial and Ethnic Disparities in Adoption of Novel CGRP Therapies for Migraine Prevention: A Retrospective Cohort Study Using the Komodo Research Dataset</a>
 SA18	<a href="#">Patient Identification for Rare Diseases With Recent ICD-10-CM Designation Using Claims Data</a>

EE176	<a href="#">Real World Economic Burden and Treatment Patterns in Idiopathic Pulmonary Fibrosis: Underutilization of Generic Pirfenidone Despite Lower Cost Burden - A Retrospective U.S. Claims Study</a>
EE190	<a href="#">Real-World (RW) Disease Progression and Healthcare Resource Utilization (HCRU) Among Patients With IGA Nephropathy (IGAN) in the United States (US)</a>
EE120	<a href="#">Excess Healthcare Costs of Overt Hepatic Encephalopathy (OHE) Relative to Non-Ohe Cirrhosis in the United States</a>
HSD31	<a href="#">Utilization of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAS) for Weight Loss and Diabetes: A State-Level Analysis Across Payer Types</a>
<b>Poster Session 3: Tuesday, May 19, 10:30 am to 1:30 pm</b>	
 HSD55	<a href="#">Uptake of Biosimilars to Insulin Glargine in 2021-2025 in the United States</a>
EE231	<a href="#">Healthcare Resource Utilization Following Human Metapneumovirus (HMPV) or Respiratory Syncytial Virus (RSV) Diagnosis in Adults: A Retrospective, Self-Controlled, Claims-Based Study in the United States</a>
EE258	<a href="#">Increased Healthcare Costs and Resource Utilization Following Progression in Patients With HR+/HER2- Metastatic Breast Cancer Receiving Chemotherapy</a>
PCR85	<a href="#">Adherence and Persistence in US Real-World New Prep Users: Cabotegravir vs Emtricitabine/Tenofovir Alafenamide</a>
RWD92	<a href="#">Portability of Performance Status Calculations in Real-World Cancer Care</a>
CO95	<a href="#">Real-World Impact of Olanzapine and Samidorphan on Rates of Relapse Among Young Adults With Schizophrenia or Bipolar I Disorder</a>
<b>Poster Session 4: Tuesday, May 19, 4 to 7 pm</b>	
EE332	<a href="#">Incremental Healthcare Costs Associated With Decompensation Events Among Patients With Cirrhosis in the United States</a>
EE375	<a href="#">Distinct Care Pathways and Economic Impact in Treated GEP-NET: A U.S. Claims Analysis of Metastatic vs Non-Metastatic Disease</a>
HSD79	<a href="#">Association Between Telehealth-Delivered Nutrition Therapy and Risk of New-Onset Obesity in Adults With Type 2 Diabetes: A Propensity Score-Matched Survival Analysis</a>
CO138	<a href="#">Real-World Comparison of Olanzapine/Samidorphan vs Olanzapine: An Assessment of Treatment Patterns and Acute Care Events Among Patients With Schizophrenia or Bipolar I Disorder</a>
<b>Poster Session 5: Wednesday, May 20, 9 to 11:30 am</b>	
EE462	<a href="#">Treatment Patterns and Healthcare Resource Utilization Among Patients With Localized Prostate Cancer Treated With External Beam Radiation Therapy</a>
HSD105	<a href="#">Real-World Clinical Characteristics and Factors Associated With Concurrent Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Therapy Among Patients With Metabolic Dysfunction-Associated Steatohepatitis (MASH) Prescribed Resmetirom</a>
HSD106	<a href="#">Pathways of Care and Access to Rifaximin Post-Discharge in Medicare-Insured Patients With Overt Hepatic Encephalopathy</a>